The purpose of this study is to examine how well this combination of trifluridine/tipiracil and nanoliposomal irinotecan works in treating patients with advanced cholangiocarcinoma or gallbladder carcinoma after their previous gemcitabine-based treatment has failed. The study will look at how long patients can go without their disease getting worse, which is measured from the time they start the study treatment until their cancer grows or spreads, or until death occurs. The study will also evaluate how long patients survive overall, how many patients experience shrinkage of their tumors, what side effects occur and how serious they are, and how the treatment affects patients’ quality of life.

During the study, patients will receive the combination treatment and will be regularly checked to see how their disease is responding. Doctors will use imaging tests to monitor the cancer and will assess any side effects that occur. The study will also use questionnaires to understand how the treatment affects patients’ daily life and well-being. Patients who have had testing to identify specific changes in their tumor may only join the study if they are not suitable for other approved targeted treatments or if they choose not to receive those treatments.

The purpose of the study is to learn more about how well the treatment works and how safe it is for participants. The study will involve taking the medication by mouth for a period of up to 36 months. Participants will be monitored regularly to see how their tumors respond to the treatment and to check for any side effects. The study will also look at how long the treatment keeps the disease under control and how it affects the overall health and quality of life of the participants.

Participants in the study will have regular check-ups and tests to track their progress. These tests will help researchers understand the effectiveness of the treatment and any potential risks. The study aims to provide valuable information that could lead to better treatment options for people with these types of tumors in the future.

The purpose of this research is to determine how safe the medication is, how it moves through the body, and how effective it is in treating these types of cancer. The study is divided into two parts. In the first part, different doses of the medication will be tested to find the most appropriate amount. In the second part, researchers will evaluate how well the medication works in treating the cancer.

During the study, participants will take CYC140 once daily for 28-day cycles. The treatment will continue as long as it remains beneficial for the patient. Throughout the study, doctors will monitor patients’ health status and how their cancer responds to the treatment. Various medical assessments will be performed to track the progress of the treatment and ensure patient safety.

The purpose of this study is to assess how well these treatments work together in preventing the return of cancer after surgery. Participants in the study will receive either the combination of durvalumab and tremelimumab with capecitabine or without capecitabine. The study will monitor the participants over a period of time to see if the cancer comes back and to evaluate their overall survival and quality of life. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

Throughout the study, participants will undergo regular check-ups and tests to monitor their health and the effects of the treatment. The study aims to gather information on the safety of the treatments and their impact on liver function, as well as to collect tissue and blood samples for future research. The study is expected to last until April 2025, with the goal of improving treatment options for patients with biliary tract cancer.

The purpose of this study is to evaluate how effective the combination of gemcitabine and cisplatin is compared to the standard care in preventing the return of cancer after surgery. Patients participating in the study will receive either the combination of gemcitabine and cisplatin or the standard care, which could be observation alone or capecitabine, depending on the stage of their cancer. The study will monitor patients over a period to see how well the treatment works in keeping the cancer from returning and to assess the overall health and quality of life of the patients.

Participants in the study will receive treatment for a set period, and their health will be closely monitored by healthcare professionals. The study aims to provide valuable information on the best treatment options for patients who have had surgery for cholangiocarcinoma or muscle invasive gallbladder carcinoma. By comparing the new treatment with the standard care, researchers hope to find the most effective way to help patients live longer without the cancer returning.

The purpose of this study is to evaluate the safety and effectiveness of these medications when used together. Participants in the study will receive the combination of these medications and will be monitored for any side effects and how their cancer responds to the treatment. The study will take place over a period of time, during which participants will have regular check-ups and assessments to track their progress. The study aims to understand how well the combination of these medications can help in treating the different types of cancer mentioned.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the treatment affects their cancer. The study will help researchers learn more about the potential benefits and risks of using Pembrolizumab, Lenvatinib, and Belzutifan together, which could lead to new treatment options for patients with these types of cancer in the future.

Participants in the study will receive the treatment over a period of 24 months. The treatment involves administering the medications through an intravenous infusion, which means they are given directly into the bloodstream through a vein. The study will also include a group of participants who will receive a placebo, which is a substance with no active medication, to compare the effects of the treatment. Throughout the study, participants will be regularly monitored to evaluate their response to the treatment and to ensure their safety.

The main goal is to see how many participants experience a reduction in their cancer size or symptoms after six months of treatment. The study will also look at how long participants live without the cancer getting worse and overall survival rates. Additionally, the safety of the treatment will be assessed by recording any side effects experienced by the participants. This trial aims to provide valuable information on the potential benefits and risks of using this combination of medications for treating HER2-positive biliary tract cancer.

The purpose of this study is to evaluate how well these treatments work in shrinking tumors and stopping cancer from growing, as well as to assess their safety. Participants will receive these treatments through infusions, which means the medication is given directly into the bloodstream through a vein, or in the form of capsules or tablets taken by mouth. The study will last for up to 12 months, during which participants will be closely monitored by healthcare professionals to track their response to the treatment and any side effects they may experience.

Throughout the study, researchers will collect information on how the cancer responds to the treatments, how long the response lasts, and the overall survival of participants. They will also measure the levels of the immunomodulators in the blood and check for any immune reactions to these new treatments. This information will help determine the potential benefits and risks of these new therapies for people with advanced hepatobiliary cancer.